|
1
|
Ahmed N, Grover NS. Race and insurance: real-world insights on CAR-T outcomes. Blood Adv 2024; 8:2589-2591. [PMID: 38805219 DOI: 10.1182/bloodadvances.2024013148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2024] Open
Affiliation(s)
- Nausheen Ahmed
- Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, KS
| | - Natalie S Grover
- Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC
- Division of Hematology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC
| |
Collapse
|
|
2
|
Derman BA. Maybe you can't drive this CAR? Blood Adv 2024; 8:1030-1031. [PMID: 38411994 PMCID: PMC10920104 DOI: 10.1182/bloodadvances.2023012244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2024] Open
|
|
3
|
Prasad V. T-Cell Lymphoma From CAR T-Cell Therapy-A New Safety Notice. JAMA 2024; 331:389-390. [PMID: 38206604 DOI: 10.1001/jama.2023.27885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2024]
Abstract
This Viewpoint outlines a recent safety signal identified by the FDA concerning CAR T-cell therapy for pediatric cancer, including what is known and likely implications.
Collapse
Affiliation(s)
- Vinay Prasad
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco
| |
Collapse
|